Name:	espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.

No definition available.

Name:	espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Cash Payment To Be Received Upon Certain Commercial Milestones

No definition available.

Name:	espr_CashPaymentToBeReceivedUponCertainCommercialMilestones
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The amount of cash payment to the Company upon first commercial sales in the DSE Territory.

No definition available.

Name:	espr_CashPaymentToBeReceivedUponFirstCommercialSales
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Deferred Up-Front Payment

No definition available.

Name:	espr_DeferredUpFrontPayment
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.

No definition available.

Name:	espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.

No definition available.

Name:	espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.

No definition available.

Name:	espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.

No definition available.

Name:	espr_FuturePaymentMilestoneSalesMilestones
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Future Up-Front Payment

No definition available.

Name:	espr_FutureUpFrontPayment
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The percentage of royalties to be received on net sales.

No definition available.

Name:	espr_PercentageOfRoyaltiesToBeReceivedOnNetSales
Namespace Prefix:	espr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

The amount of up-front payment received (paid) .

No definition available.

Name:	espr_UpFrontPayment
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Name:	srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=espr_RoyaltyRevenueAndProductSalesBulkTabletsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: